Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leuprorelin - Tolmar

Drug Profile

Leuprorelin - Tolmar

Alternative Names: Eligard; FENSOLVI; LA 2575; Leuprogel®; Leuprolide acetate - Tolmar; SOT-375; TOL-2506

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QLT USA
  • Developer MediGene AG; Tolmar
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Precocious puberty; Prostate cancer
  • Phase III HER2 negative breast cancer
  • Discontinued Endometriosis

Most Recent Events

  • 26 Jan 2023 Phase-III clinical trials in HER2-negative-breast-cancer (Combination therapy) in Puerto Rico, Mexico (SC, Injection) (NCT04906395)
  • 13 Dec 2022 Tolmar initiates a phase III trial for Breast cancer (Combination therapy) in USA (Injection) (NCT05645536)
  • 08 Oct 2021 Leuprorelin is no more licensed to Sanofi in Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top